Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05907304 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Erasca.

Active
Registry status
Phase 1
Development phase
86
Enrollment target
20
Study locations

NCT05907304 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Erasca. The registered enrollment target is 86 participants, below the 232-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 18 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05907304, a Phase 1 study of Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Erasca.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
86 participants
Enrollment target
20
Study locations

Study Summary

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG Trametinib
  • DRUG Naporafenib

Study Locations (20)

Florida

  • Florida Cancer Specialists - Sarasota - Sarasota
  • Florida Cancer Specialists - St. Petersburg - St. Petersburg

Virginia

  • Inova Schar Cancer Institute - Fairfax
  • NEXT Virginia - Fairfax

California

  • University of California, San Francisco - San Francisco

Connecticut

  • Yale Cancer Center - New Haven

Georgia

  • Emory University School of Medicine - Atlanta

Michigan

  • Henry Ford Health System - Detroit

Missouri

  • Washington University School of Medicine - St Louis

Nevada

  • Comprehensive Cancer Center of Nevada (CCCN) - Las Vegas

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2023-08-17
Est. Completion 2026-12
Phase Phase 1

Sponsor

Erasca

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05907304

The ClinicalTrials.gov registry entry for NCT05907304 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target (63% lower). The listed sponsor is Erasca, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Trametinib is the first listed.

NCT05907304 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Florida, Virginia, California.

Frequently Asked Questions

What is clinical trial NCT05907304 about?

NCT05907304 is a clinical study titled "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations". To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic...

What is the current status of trial NCT05907304?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-08-17. Estimated completion is 2026-12.

What conditions does trial NCT05907304 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT05907304?

The interventions under investigation include: Trametinib (DRUG), Naporafenib (DRUG).

Who is sponsoring clinical trial NCT05907304?

This trial is sponsored by Erasca, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05907304 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.